Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Common Equity (2016 - 2025)

Adma Biologics' Common Equity history spans 14 years, with the latest figure at $477.3 million for Q4 2025.

  • For Q4 2025, Common Equity rose 36.76% year-over-year to $477.3 million; the TTM value through Dec 2025 reached $477.3 million, up 36.76%, while the annual FY2025 figure was $477.3 million, 36.76% up from the prior year.
  • Common Equity reached $477.3 million in Q4 2025 per ADMA's latest filing, up from $431.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $477.3 million in Q4 2025 to a low of $100.4 million in Q3 2022.
  • Average Common Equity over 5 years is $207.2 million, with a median of $149.1 million recorded in 2023.
  • Peak YoY movement for Common Equity: fell 11.03% in 2023, then skyrocketed 158.14% in 2024.
  • A 5-year view of Common Equity shows it stood at $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then fell by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then soared by 36.76% to $477.3 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Common Equity are $477.3 million (Q4 2025), $431.2 million (Q3 2025), and $398.3 million (Q2 2025).